Drug Test Systems Newsletter - The Dispatch

Drug Test News from Drug Test Systems

Welcome to the First Edition

One of the many objectives of DTS during the new year is to provide our customers with meaningful and timely information pertaining to the drug and alcohol testing industry. It is our intent to communicate interesting news and reference materials on a regular basis. While the initial editions of The Dispatch will be printed and delivered as order stuffers and included with customer shipments, we fully intend to transition the periodical into an electronic newsletter and communicate via email. Please “opt in” to receive the future electronic editions of The Dispatch by sending us an email indicating the same. Please send your email to dispatch@drugtestsystems.com (or entering on our web site).

Introducing DTS

Ordering Options

About CLIA

Introducing DTS

We thought it appropriate to include a formal introduction of our staff and facility in the first edition of the Dispatch. DTS and its staff have been privileged by having enjoyed quality, longstanding relationships with a great number of our customers. We truly value our customer relationships and we appreciate your business. We thought that you would enjoy seeing our office/warehouse and connecting the face with the voice.

Dover, NH Facility Unit 4/5 to right	Bob Witkop, President Julie "JJ" Horner, Marketing Director	Brooke Conlin Operations

[top]

Ordering Options

New! Order Via Email

Did you know that DTS customers are provided with four options for placing orders?

1) Telephone at 888-805-4849

2) Fax at 603-749-1119

3) Internet at www.drugtestsystems.com

4) Email at orders@drugtestsystems.com

[top]

About CLIA

Overview / Background

Congress enacted the Clinical Laboratory Improvement Amendments (“CLIA”) in 1988 to ensure the accuracy and reliability of all laboratory testing. This legislation, for the first time, extended federal regulation to all laboratories that perform testing on human specimens for the purpose of diagnosing or treating disease, illness, or assessment of human beings. The objective of the CLIA program is to insure quality laboratory testing.

Prior to CLIA, federal regulation of laboratory testing was limited to testing performed in independent laboratories and hospitals. The CLIA statute extended regulation to all types of testing sites and based regulation on the complexity of tests, not the type of lab where the testing occurs. Thus, laboratories performing similar tests must meet similar standards, whether located in a hospital, doctor’s office or other site.

CLIA requires all entities that perform even one test, including a CLIA waived test on…”materials derived from the human body for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of human beings” to meet certain Federal requirements. If an entity performs tests for these purposes, it is considered under CLIA to be a laboratory and must register with the CLIA program.

All clinical laboratories must be properly certified to receive Medicare or Medicaid payments.

On September 5, 2008, CLIA released a memorandum that restates an ongoing policy that laboratories performing drug or alcohol screening and/or testing followed by individual treatment must be CLIA certified.

State survey agencies, typically state health departments are responsible for oversight of the CLIA program.

CLIA established three categories of laboratory tests: waived tests, moderately complex tests, and highly complex tests. Waived tests – simple tests with small chance of error or risk are exempt from virtually all CLIA rules, so long as testing is performed in strict compliance with the manufacturers’ instructions. Moderate and high complexity tests are subject to regulations setting minimum qualifications for all persons performing or supervising these tests. These laboratories must also participate successfully in approved proficiency testing programs.

CLIA Waived Tests and Facilities

By the CLIA law, certificate of waiver (COW) laboratories perform only tests that are determined by the FDA or CDC to be so simple (CLIA Waived) that there is little risk of error.

The COW laboratories must meet only the following requirements under CLIA:
a) Enroll in the CLIA program;
b) Pay applicable certificate fees biannually; and
c) Follow manufacturers test instructions.

Application for a CLIA Certificate
The Centers for Medicare and Medicaid Services (CMS) has made available the Clinical Laboratory Amendments Application for certification Form, CMS-116. This form should be completed and mailed to the address of the local state Agency for the state in which the testing will be performed. For additional details contact Drug Test Systems or visit www.cms.hhs.gov/CLIA/06.

The current fee for obtaining a CLIA Waived certificate is $150.00. The CLIA Waived certificate is valid for 2 years.

[top]